Immune checkpoints in cancer clinical trials

Chinese Journal of Cancer

Volumn 33, Issue 9, 2014, Pages 434-444

  Sharon, Elad ^a   Streicher, Howard ^a   Goncalves, Priscila ^a   Chen, Helen X ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CTLA4; Immune checkpoints; Immune modulators; Immunotherapy; PD 1; PD L1

Indexed keywords

AUND 12; CD28 ANTIGEN; CD40 ANTIGEN; CELL MEMBRANE PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; DOCETAXEL; EVEROLIMUS; GALIXIMAB; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; IMMUNOMODULATING AGENT; INDOLEAMINE 2, 3 DIOXYGENASE; IPILIMUMAB; MEDI4736; MOGAMULIZUMAB; MPDL 3280A; MSB0010718C; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; STAT3 PROTEIN; T LYMPHOCYTE RECEPTOR; TICILIMUMAB; UNCLASSIFIED DRUG; VARLILUMAB; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CASTRATION RESISTANT PROSTATE CANCER; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; FATIGUE; FOLLICULAR LYMPHOMA; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALIGNANT MESOTHELIOMA; MELANOMA; METASTATIC MELANOMA; NEOPLASM; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRURITUS; RASH; RECURRENCE FREE SURVIVAL; REVIEW; SOLID TUMOR; T CELL LEUKEMIA; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; CELL CYCLE CHECKPOINT; IMMUNOLOGY; IMMUNOTHERAPY; MORTALITY; PROCEDURES;

ANTIGENS, CD274; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; CELL CYCLE CHECKPOINTS; CTLA-4 ANTIGEN; IMMUNOTHERAPY; MELANOMA; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84907501302     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.014.10122     Document Type: Review

References (73)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012,12:252-264.
2. Hotchkiss RS, Moldawer LL. Parallels between cancer and infectious disease. N Engl J Med, 2014,371:380-383.
3. Hamanishi J, Mandai M, Ikeda T, et al. Efficacy and safety of anti- PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. J Clin Oncol, 2014,32 suppl: abstr 5511.
4. Seiwert TY, Burtness B, Weiss J, et al. A phase Ib study of MK- 3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. J Clin Oncol, 2014,32 suppl:abstr 6011.
5. Powles T, Vogelzang NJ, Fine GD, et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). J Clin Oncol, 2014,32 suppl:abstr 5011.
6. Bachy E, Coiffier B. Anti- PD1 antibody: a new approach to treatment of lymphomas. Lancet Oncol, 2014,15:7-8.
7. Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol, 2013,31:4199-4206.
8. Malas S, Harrasser M, Lacy KE, et al. Antibody therapies for melanoma: new and emerging opportunities to activate immunity. Oncol Rep, 2014. [Epub ahead of print]
9. Srivastava N, McDermott D. Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Manage Res, 2014,6:279-289.
10. Sundar R, Soong R, Cho BC, et al. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer, 2014,85:101-109.
11. Gunturi A, McDermott DF. Potential of new therapies like anti-PD1 in kidney cancer. Curr Treat Options Oncol, 2014,15:137-146.
12. Kennedy E, Rossi GR, Vahanian NN, et al. Phase 1/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus ipilimumab for the treatment of unresectable stage 3 or 4 melanoma. J Clin Oncol, 2014,32 suppl:abstr TPS9117.
13. Khleif S, Munn D, Nyak-Kapoor A, et al. First-in-human phase 1 study of the novel indoleamine-2,3-dioxygenase (IDO) inhibitor NLG-919. J Clin Oncol, 2014,32 suppl:abstr TPS3121.
14. Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, et al. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest New Drugs, 2013,31:707-713.
15. Ferris RL, Lu B, Kane LP. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J Immunol, 2014,193:1525-1530.
16. Ok CY, Chen J, Xu-Monette Z, et al. Clinical implications of phosphorylated STAT3 expression in de novo diffuse large B-cell lymphoma. Clin Cancer Res, 2014. [Epub ahead of print]
17. Lu L, Xu X, Zhang B, et al. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Transl Med, 2014,12:36.
18. Benson DM Jr, Hofmeister CC, Padmanabhan S, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/ refractory multiple myeloma. Blood, 2012,120:4324-4333.
19. Vey N, Bourhis JH, Boissel N, et al. A phase 1 trial of the anti- inhibitory KIR mAb IPH2101 for AML in complete remission. Blood, 2012,120:4317-4323.
20. Kohrt HE, Thielens A, Marabelle A, et al. Anti- KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood, 2014,123:678-686.
21. Linsley PS, Brady W, Grosmaire L, et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med, 1991,173:721-730.
22. Blank CU, Enk A. Therapeutic use of anti-CTLA-4 antibodies. Int Immunol, 2014. [Epub ahead of print]
23. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science, 1996,271:1734-1736.
24. Quezada SA, Peggs KS, Curran MA, et al. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest, 2006,116:1935-1945.
25. Curran MA, Montalvo W, Yagita H, et al. PD - 1 and CTLA- 4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A, 2010,107:4275-4280.
26. Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science, 2011,332:600-603.
27. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol, 2002,3:1097-1101.
28. Magistrelli G, Jeannin P, Herbault N, et al. A soluble form of CTLA- 4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol, 1999,29:3596-3602.
29. Hodi FS, O’Day SJ, McDermott D., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010,363:711-723.
30. Tarhini AA, Thalanayar PM. Melanoma adjuvant therapy. Hematol Oncol Clin North Am, 2014,28:471-489.
31. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med, 2011,364:2517-2526.
32. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. J Clin Oncol, 2014,32 suppl:abstr LBA9008.
33. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa- 2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol, 1996,14:7-17.
34. Hu JL, Sharma P, Yu J, et al. Ipilimumab for recurrent glioblastoma: a single-institution case series. J Clin Oncol, 2014,32 suppl:abstr e13010.
35. Snyder Charen A, Makarov V, Merghoub T, et al. The neoantigen landscape underlying clinical response to ipilimumab. J Clin Oncol, 2014,32 suppl:abstr 3003.
36. Kirkwood JM, Lorigan P, Hersey P, et al. PhaseIItrial o f tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res, 2010,16:1042-1048.
37. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol, 2013,31:616-622.
38. Calabro L, Morra A, Fonsatti E, et al. A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients. J Clin Oncol, 2014,32 suppl:abstr 7531.
39. Maio M, Scherpereel A, Di Pietro A, et al. Randomized, double- blind, placebo-controlled study of tremelimumab for second- and third-line treatment of unresectable pleural or peritoneal mesothelioma. J Clin Oncol, 2014,32 suppl:abstr TPS7609.
40. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev, 2010,236:219-242.
41. Pedoeem A, Azoulay-Alfaguter I, Strazza M, et al. Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol, 2014,153:145-152.
42. Nicholas KJ, Zern EK, Barnett L, et al. B cell responses to HIV antigen are a potent correlate of viremia in HIV-1 infection and improve with PD-1 blockade. PloS One, 2013,8:e84185
43. Kim JR, Moon YJ, Kwon KS, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PloS One, 2013,8:e82870.
44. Maine CJ, Aziz NH, Chatterjee J, et al. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother, 2014,63:215-224.
45. Muenst S, Schaerli AR, Gao F, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat, 2014,146:15-24.
46. Oba J, Nakahara T, Abe T, et al. Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival. J Am Acad Dermatol, 2014,70:954-956.
47. Shi SJ, Wang LJ, Wang GD, et al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PloS One, 2013,8:e76012.
48. Tamai K, Nakamura M, Mizuma M, et al. Suppressive expression of CD274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma. Cancer Sci, 2014,105:667-674.
49. Xylinas E, Robinson BD, Kluth LA, et al. Association of T-cell co- regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol, 2014,40:121-127.
50. Zhang Y, Wang L, Li Y, et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther, 2014,7:567-573.
51. Zheng Z, Bu Z, Liu X, et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res, 2014,26:104-111.
52. Liu Y, Carlsson R, Ambjorn M, et al. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. J Neurosci, 2013,33:14231-14245.
53. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 2012,366:2443-2454.
54. Topalian SL, Sznol M, McDermott D., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol, 2014,32:1020-1030.
55. Gettinger SN, Shepherd FA, Antonia SJ, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol, 2014,32 suppl:abstr 8024.
56. Antonia SJ, Brahmer JR, Gettinger SN, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 2014,32 suppl:abstr 8113.
57. Rizvi NA, Chow LQM, Borghaei H, et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. J Clin Oncol, 2014,32 suppl:abstr 8022.
58. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med, 2013,369:134-144.
59. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death- receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, 2014. [Epub ahead of print]
60. Ribas A, Hodi FS, Kefford R, et al. Efficacy and safety of the anti- PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol, 2014,32 suppl:abstr LBA9000.
61. Garon EB, Leighl NB, Rizvi NA, et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol, 2014,32 suppl:abstr 8020.
62. Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett, 2014,588:368-376.
63. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol, 2014,15:69-77.
64. Atkins MB, Kudchadkar RR, Sznol M, et al. Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. J Clin Oncol, 2014,32 suppl:abstr 9001.
65. Herbst RS, Gordon MS, Fine GD, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol, 2013,31 suppl:abstr 3000.
66. Spigel DR, Gettinger SN, Horn L, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol, 2013,31 suppl:abstr 8008.
67. Cho DC, Sosman JA, Sznol M, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol, 2013,31 suppl:abstr 4505.
68. Hamid O, Sosman JA, Lawrence DP, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol, 2013,31 suppl:abstr 9010.
69. Tabernero J, Powderly JD, Hamid O, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors. J Clin Oncol, 2013,31 suppl:abstr 3622.
70. Khleif S, Lutzky J, Segal N, et al. MEDI4736, an anti-PD-L1 antibody with modified Fc domain: preclinical evaluation and early clinical results from a phase 1 study in patients with advanced solid tumors. Eur J Cancer, 2013:S161-S161.
71. Fairman D, Narwal R, Liang M, et al. Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol, 2014,32 suppl:abstr 2602.
72. Brahmer JR, Rizvi NA, Lutzky J, et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. J Clin Oncol, 2014,32 suppl:abstr 8021.
73. Hodi FS, Lee SJ, McDermott D., et al. Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (IPI) versus IPI alone in metastatic melanoma: E1608. J Clin Oncol, 2013,31 suppl:abstr CFVt-0007.